Congestive heart failure. Fluid retention (ascites and oedema) in liver cirrhosis. Overproduction of aldosterone, a steroid hormone which regulates the salt and water balance in the body (hyperaldosteronism). To treat excess fluid retention causing swelling (oedema).
Furosemide: loop diuretic, Spironolactone: potassium-sparing diuretic
Tablet: 100 mg qDay or divided q12hr for 5 days initially; then adjust does based on patient response; range: 25-200 mg PO qDay or divided q12hr
This medicine may cause fatigue and dizziness. You should take care when performing potentially hazardous activities, such as driving or operating machinery, until you know how this medicine affects you and are sure you can perform such activities safely. While taking this medicine you may need to have regular blood tests to monitor your kidney function and the levels of salts such as potassium and sodium in your blood. If you experience any of the following symptoms while taking this medicine you should inform your doctor promptly, so that the amount of fluids and salts in your body can be checked: thirst, lethargy, confusion, weakness, drowsiness, muscle cramps, scanty production of urine, abnormal heart rhythm, seizures, nausea and vomiting.
Increased production of urine. Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting or abdominal pain. Dehydration. Decrease in blood pressure. Dizziness. Drowsiness. Weakness. Dry mouth. Headache. Confusion. Visual disturbances. Muscle cramps. Skin rashes. Increased blood sugar level. Increased level of uric acid in the blood (hyperuricaemia) which may cause gout. Disturbances in the levels of electrolytes (eg potassium, calcium, magnesium) in the blood. Pins and needles (paraesthesia). Sensation of ringing or other noise in the ears (tinnitus). Abnormal enlargement of breasts in men (gynaecomastia). Changes in libido. Disturbance in the normal numbers of blood cells in the blood. Severe blistering skin reactions, eg Stevens-Johnson Syndrome.
Results of animal work, in general, show no hazardous effect of furosemide in pregnancy. There is clinical evidence of safety of the drug in the third trimester of human pregnancy; however, furosemide crosses the placental barrier. Spironolactone or its metabolites may cross the placental barrier. Animal studies have shown feminisation of the genitalia in male offspring. Anti-androgenic effects have been reported in humans with the risk of ambiguous external genitalia in male newborns. Lasilactone must not be used in pregnancy unless there are compelling medical reasons. Treatment during pregnancy requires monitoring of foetal growth.Furosemide passes into breast milk and may inhibit lactation. Canerone, a metabolite of spironolactone, appears in breast milk and Lasilactone must therefore not be used in breast-feeding mothers.
.png&w=384&q=75)